Dr. Alex Zaboronkov, Founder and CEO of Insilico Medicine, was invited to attend BIO Asia-Taiwan in Taiwan, China from July 15th to 19th.
Dr. Zaboronkov will give a keynote address with the following title: How to build a sustainable and long-lived company July 15th at 11:40am in the main forum. Furthermore, I will participate in a panel discussion on July 16th from 11:55 am. AI × Medicine: Reshaping the future of drug discovery Join industry experts to explore the disruptive innovation and transformation that AI is bringing to the pharmaceutical industry.
Building a sustainable, long-lived company requires more than a bold mission. We need a scalable engine for innovation. This talk will explore how generative AI and automation are transforming drug and materials discovery, shortening timelines from target identification to nomination for development, and enabling new models in biotechnology that can grow, learn, and compound value over time. Based on real-world experiences at Insilico Medicine, this session explores key pillars of sustainability: scientific productivity as measured by rigorous benchmarks, a portfolio strategy that balances in-house advancements and licenses, and an AI platform that improves with each program we run.
About BIO Asia Taiwan 2026
BIO Asia-Taiwan 2026 will be grandly held at Taipei Nangang Exhibition Center from July 15th to 19th, 2026.
This year’s conference, themed “Asian Inspiration, Global Impact,” will attract more than 850 exhibitors and 2,200 booths from approximately 60 countries and regions around the world. Asia’s largest biotech event, the 2026 conference will focus in-depth on core areas such as cutting-edge biopharmaceutical R&D, cross-border digital health, AI-driven healthcare, and CDMO manufacturing. The event aims to create the most efficient platform for cross-border cooperation and capital matching for the world’s life sciences leaders through international forums, one-on-one business partner sessions, and a large-scale exhibition.
